Skip to main content
. 2016 Aug 30;17(10):1079–1088. doi: 10.1080/15384047.2016.1219819

Figure 7.

Figure 7.

Studies with compound GHDM-1515 in ovc-rNanog/DsRed cells. (A) Structure of compound GHDM-1515. (B) Flow cytometry-based analysis of apoptosis. Apoptotic cells were defined as Annexin V-positive/7-AAD-negative. (C) Percentage of apoptotic cells after treatment with cisplatin (2.5 μM) and GHDM-1515 (2 μM) for 4 or 8 days. Two settings of combination treatment were tested. Cells were pre-incubated with GHDM-1515 for 24h before adding cisplatin (GHDM-1515cisplatin) or drugs were mixed (GHDM-1515 + cisplatin). SD-83, a compound that did not block cisplatin-triggered MAPK activation (see Fig. 5) was used as a control. N = 3. (D) Percentage of apoptotic cells in the fraction of putative CSCs, i.e. rNanog/DsRed-positive cells.